Ultragenyx Pharmaceutical (NASDAQ:RARE) Announces Earnings Results

Ultragenyx Pharmaceutical (NASDAQ:RARE) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($2.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.72) by ($0.31), Briefing.com reports. The firm had revenue of $108.83 million for the quarter, compared to analyst estimates of $116.03 million. Ultragenyx Pharmaceutical had a negative return on equity of 421.88% and a negative net margin of 138.58%. The company’s quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter in the previous year, the company earned ($2.33) earnings per share.

Ultragenyx Pharmaceutical Trading Down 1.0 %

Shares of NASDAQ RARE opened at $42.75 on Friday. Ultragenyx Pharmaceutical has a 1 year low of $31.52 and a 1 year high of $54.98. The company has a 50 day simple moving average of $47.25 and a 200 day simple moving average of $44.14.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, EVP Thomas Richard Kassberg sold 11,509 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $49.93, for a total transaction of $574,644.37. Following the completion of the transaction, the executive vice president now owns 252,823 shares in the company, valued at approximately $12,623,452.39. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Ultragenyx Pharmaceutical news, insider John Richard Pinion sold 4,173 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $53.76, for a total transaction of $224,340.48. Following the completion of the transaction, the insider now owns 89,268 shares in the company, valued at approximately $4,799,047.68. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Thomas Richard Kassberg sold 11,509 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, March 11th. The shares were sold at an average price of $49.93, for a total transaction of $574,644.37. Following the completion of the sale, the executive vice president now owns 252,823 shares of the company’s stock, valued at approximately $12,623,452.39. The disclosure for this sale can be found here. In the last 90 days, insiders sold 32,116 shares of company stock worth $1,645,983. 6.80% of the stock is currently owned by insiders.

Analysts Set New Price Targets

RARE has been the topic of a number of analyst reports. Wedbush reduced their price objective on shares of Ultragenyx Pharmaceutical from $48.00 to $47.00 and set a “neutral” rating on the stock in a research note on Friday. Royal Bank of Canada initiated coverage on shares of Ultragenyx Pharmaceutical in a research note on Monday, April 22nd. They issued an “outperform” rating and a $77.00 price target on the stock. Robert W. Baird raised their price target on shares of Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the company an “outperform” rating in a research note on Tuesday, January 30th. Cantor Fitzgerald restated an “overweight” rating and issued a $107.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday. Finally, Canaccord Genuity Group raised their price target on shares of Ultragenyx Pharmaceutical from $110.00 to $111.00 and gave the company a “buy” rating in a research note on Wednesday, February 21st. Two equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $88.00.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.